Tapentadol in Chronic Malignant Tumour Related Pain

Summary

The purpose of this trial is the characterization of the long term safety profile and long-term dose requirements of tapentadol PR (prolonged release) in patients with malignant tumor-related pain. In the United States the prolonged-release formulation is also referred to as the extended-release formulation.

Timeline

Start

2011-03

Primary completion

2014-05

Completion

2014-05

Drugs

Indications